Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
TGN1412: From Discovery to Disaster.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
New insights into signaling during myelination in zebrafish.
Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Biogen Idec's PLEGRIDY™ (peginterferon beta-1a) approved in the US for the treatment of multiple sclerosis
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.

Pages